Annual Cash & Cash Equivalents
$2.00 M
-$2.23 M-52.83%
31 December 2022
Summary:
Navidea Biopharmaceuticals annual cash & cash equivalents is currently $2.00 million, with the most recent change of -$2.23 million (-52.83%) on 31 December 2022. During the last 3 years, it has fallen by -$674.60 thousand (-25.26%). NAVB annual cash & cash equivalents is now -93.94% below its all-time high of $32.94 million, reached on 31 December 2013.NAVB Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$3.86 M
-$2.28 M-37.10%
30 September 2023
Summary:
Navidea Biopharmaceuticals quarterly cash and cash equivalents is currently $3.86 million, with the most recent change of -$2.28 million (-37.10%) on 30 September 2023. NAVB quarterly cash and cash equivalents is now -91.34% below its all-time high of $44.63 million, reached on 30 September 2013.NAVB Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NAVB Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | -25.3% | -46.1% |
| 5 y5 years | -42.6% | +36.0% |
NAVB Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -52.8% | at low | -46.1% | >+9999.0% |
| 5 y | 5 years | -52.8% | +90.6% | -48.5% | >+9999.0% |
| alltime | all time | -93.9% | +184.9% | -91.3% | >+9999.0% |
Navidea Biopharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2023 | - | $3.86 M(-37.1%) |
| June 2023 | - | $6.14 M(>+9900.0%) |
| Mar 2023 | - | $33.80 K(-98.3%) |
| Dec 2022 | $2.00 M(-52.8%) | $2.00 M(-56.6%) |
| Sept 2022 | - | $4.60 M(+1302.7%) |
| June 2022 | - | $328.00 K(-73.1%) |
| Mar 2022 | - | $1.22 M(-71.2%) |
| Dec 2021 | $4.23 M(+58.4%) | $4.23 M(-41.0%) |
| Sept 2021 | - | $7.18 M(+0.9%) |
| June 2021 | - | $7.11 M(-5.2%) |
| Mar 2021 | - | $7.51 M(+181.1%) |
| Dec 2020 | $2.67 M(+155.0%) | $2.67 M(-28.3%) |
| Sept 2020 | - | $3.72 M(+130.2%) |
| June 2020 | - | $1.62 M(+168.9%) |
| Mar 2020 | - | $601.40 K(-42.6%) |
| Dec 2019 | $1.05 M(-69.9%) | $1.05 M(-63.1%) |
| Sept 2019 | - | $2.84 M(-43.9%) |
| June 2019 | - | $5.06 M(+244.3%) |
| Mar 2019 | - | $1.47 M(-57.7%) |
| Dec 2018 | $3.48 M(+24.4%) | $3.48 M(-39.1%) |
| Sept 2018 | - | $5.71 M(+21.7%) |
| June 2018 | - | $4.69 M(+474.2%) |
| Mar 2018 | - | $817.00 K(-70.8%) |
| Dec 2017 | $2.79 M(+81.6%) | $2.79 M(-39.5%) |
| Sept 2017 | - | $4.62 M(-18.0%) |
| June 2017 | - | $5.63 M(-58.1%) |
| Mar 2017 | - | $13.44 M(+773.2%) |
| Dec 2016 | $1.54 M(-78.5%) | $1.54 M(+89.9%) |
| Sept 2016 | - | $810.40 K(-29.9%) |
| June 2016 | - | $1.16 M(-78.9%) |
| Mar 2016 | - | $5.48 M(-23.5%) |
| Dec 2015 | $7.17 M(+30.8%) | $7.17 M(-37.0%) |
| Sept 2015 | - | $11.37 M(-28.0%) |
| June 2015 | - | $15.79 M(+223.3%) |
| Mar 2015 | - | $4.88 M(-10.9%) |
| Dec 2014 | $5.48 M(-83.4%) | $5.48 M(-47.3%) |
| Sept 2014 | - | $10.39 M(-40.5%) |
| June 2014 | - | $17.47 M(-32.8%) |
| Mar 2014 | - | $26.01 M(-21.0%) |
| Dec 2013 | $32.94 M(+261.2%) | $32.94 M(-26.2%) |
| Sept 2013 | - | $44.63 M(+74.1%) |
| June 2013 | - | $25.64 M(+160.4%) |
| Mar 2013 | - | $9.85 M(+8.0%) |
| Dec 2012 | $9.12 M(-68.2%) | $9.12 M(-18.7%) |
| Sept 2012 | - | $11.21 M(-33.9%) |
| June 2012 | - | $16.95 M(-22.6%) |
| Mar 2012 | - | $21.90 M(-23.5%) |
| Dec 2011 | $28.64 M(+346.1%) | $28.64 M(-9.8%) |
| Sept 2011 | - | $31.76 M(+321.0%) |
| June 2011 | - | $7.54 M(-22.3%) |
| Mar 2011 | - | $9.70 M(+51.1%) |
| Dec 2010 | $6.42 M(+13.8%) | $6.42 M(+145.9%) |
| Sept 2010 | - | $2.61 M(-33.8%) |
| June 2010 | - | $3.94 M(-33.8%) |
| Mar 2010 | - | $5.96 M(+5.6%) |
| Dec 2009 | $5.64 M(+58.2%) | $5.64 M(-6.5%) |
| Sept 2009 | - | $6.03 M(+92.5%) |
| June 2009 | - | $3.13 M(-11.7%) |
| Mar 2009 | - | $3.55 M(-0.5%) |
| Dec 2008 | $3.57 M | $3.57 M(+37.2%) |
| Sept 2008 | - | $2.60 M(-25.2%) |
| June 2008 | - | $3.48 M(+127.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2008 | - | $1.53 M(-0.8%) |
| Dec 2007 | $1.54 M(-38.5%) | $1.54 M(+26.3%) |
| Sept 2007 | - | $1.22 M(+1.0%) |
| June 2007 | - | $1.21 M(-39.0%) |
| Mar 2007 | - | $1.98 M(-21.0%) |
| Dec 2006 | $2.50 M(-49.3%) | $2.50 M(-31.3%) |
| Sept 2006 | - | $3.64 M(-22.9%) |
| June 2006 | - | $4.73 M(-16.5%) |
| Mar 2006 | - | $5.66 M(+14.5%) |
| Dec 2005 | $4.94 M(-49.8%) | $4.94 M(+38.8%) |
| Sept 2005 | - | $3.56 M(-22.2%) |
| June 2005 | - | $4.58 M(-15.6%) |
| Mar 2005 | - | $5.42 M(-44.9%) |
| Dec 2004 | $9.84 M(+519.5%) | $9.84 M(+227.2%) |
| Sept 2004 | - | $3.01 M(-12.3%) |
| June 2004 | - | $3.43 M(+1.2%) |
| Mar 2004 | - | $3.39 M(+113.4%) |
| Dec 2003 | $1.59 M(+126.8%) | $1.59 M(+276.0%) |
| Sept 2003 | - | $422.60 K(+14.6%) |
| June 2003 | - | $368.70 K(+4.5%) |
| Mar 2003 | - | $352.70 K(-49.7%) |
| Dec 2002 | $700.50 K(-83.7%) | $700.50 K(-60.2%) |
| Sept 2002 | - | $1.76 M(+75.4%) |
| June 2002 | - | $1.00 M(-16.8%) |
| Mar 2002 | - | $1.21 M(-71.9%) |
| Dec 2001 | $4.29 M(-7.7%) | $4.29 M(-11.9%) |
| Sept 2001 | - | $4.86 M(+8.9%) |
| June 2001 | - | $4.47 M(+18.8%) |
| Mar 2001 | - | $3.76 M(-19.0%) |
| Dec 2000 | $4.64 M(-4.9%) | $4.64 M(+42.0%) |
| Sept 2000 | - | $3.27 M(+20.8%) |
| June 2000 | - | $2.71 M(-0.3%) |
| Mar 2000 | - | $2.71 M(-9.5%) |
| Dec 1999 | $4.88 M(+359.8%) | - |
| June 1999 | - | $3.00 M(-23.1%) |
| Mar 1999 | - | $3.90 M(+267.3%) |
| Dec 1998 | $1.06 M(-89.3%) | $1.06 M(-75.9%) |
| Sept 1998 | - | $4.40 M(-26.7%) |
| June 1998 | - | $6.00 M(-27.7%) |
| Mar 1998 | - | $8.30 M(-16.3%) |
| Dec 1997 | $9.92 M(-67.1%) | $9.92 M(-45.8%) |
| Sept 1997 | - | $18.30 M(-10.7%) |
| June 1997 | - | $20.50 M(-24.9%) |
| Mar 1997 | - | $27.30 M(-9.6%) |
| Dec 1996 | $30.20 M(+202.0%) | $30.20 M(+11.4%) |
| Sept 1996 | - | $27.10 M(-8.4%) |
| June 1996 | - | $29.60 M(+199.0%) |
| Mar 1996 | - | $9.90 M(-1.0%) |
| Dec 1995 | $10.00 M(0.0%) | $10.00 M(-6.5%) |
| Sept 1995 | - | $10.70 M(+13.8%) |
| June 1995 | - | $9.40 M(+67.9%) |
| Mar 1995 | - | $5.60 M(-44.0%) |
| Dec 1994 | $10.00 M(+669.2%) | $10.00 M(+1328.6%) |
| Sept 1994 | - | $700.00 K(-22.2%) |
| June 1994 | - | $900.00 K(-18.2%) |
| Mar 1994 | - | $1.10 M(-15.4%) |
| Dec 1993 | $1.30 M(-84.9%) | $1.30 M(+116.7%) |
| Sept 1993 | - | $600.00 K(+20.0%) |
| June 1993 | - | $500.00 K(-87.5%) |
| Mar 1993 | - | $4.00 M(-53.5%) |
| Dec 1992 | $8.60 M | $8.60 M(+8500.0%) |
| Sept 1992 | - | $100.00 K |
FAQ
- What is Navidea Biopharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Navidea Biopharmaceuticals?
What is Navidea Biopharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of NAVB is $2.00 M
What is the all time high annual cash & cash equivalents for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high annual cash & cash equivalents is $32.94 M
What is Navidea Biopharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NAVB is $3.86 M
What is the all time high quarterly cash and cash equivalents for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high quarterly cash and cash equivalents is $44.63 M